Selected research
Industry Research
Chemotherapy-Induced Neutropenia Treatment Industry Research Report 2026
Market perspective
The global Chemotherapy-Induced Neutropenia Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Chemotherapy-Induced Neutropenia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Chemotherapy-Induced Neutropenia Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Chemotherapy-Induced Neutropenia Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Chemotherapy-Induced Neutropenia Treatment include Teva Pharmaceuticals Industries, Sanofi, Novartis AG, Baxter International, Amgen, Ligand Pharmaceuticals, Dr. Reddy’s Laboratory, Biogenomics Limited and Apotex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Chemotherapy-Induced Neutropenia Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Chemotherapy-Induced Neutropenia Treatment Market by Company
Teva Pharmaceuticals Industries
Sanofi
Novartis AG
Baxter International
Amgen
Ligand Pharmaceuticals
Dr. Reddy’s Laboratory
Biogenomics Limited
Apotex
Chemotherapy-Induced Neutropenia Treatment Segment by Type
Splenectomy Procedure
Granulocyte Transfusion
Antibiotic Therapy
Colony-Stimulating Factor Therapy
Others
Chemotherapy-Induced Neutropenia Treatment Segment by Application
Ambulatory Surgical Center
Hospitals
Diagnostic Centers
Chemotherapy-Induced Neutropenia Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy-Induced Neutropenia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy-Induced Neutropenia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy-Induced Neutropenia Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Chemotherapy-Induced Neutropenia Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Chemotherapy-Induced Neutropenia Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Chemotherapy-Induced Neutropenia Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Splenectomy Procedure
- Granulocyte Transfusion
- Antibiotic Therapy
- Colony-Stimulating Factor Therapy
- Others
Applications
- Ambulatory Surgical Center
- Hospitals
- Diagnostic Centers
Companies covered
- Teva Pharmaceuticals Industries
- Sanofi
- Novartis AG
- Baxter International
- Amgen
- Ligand Pharmaceuticals
- Dr. Reddy’s Laboratory
- Biogenomics Limited
- Apotex
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size (2021-2032)
- 2.2.2 Global Chemotherapy-Induced Neutropenia Treatment Sales (2021-2032)
- 2.2.3 Global Chemotherapy-Induced Neutropenia Treatment Market Average Price (2021-2032)
- 2.3 Chemotherapy-Induced Neutropenia Treatment by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Splenectomy Procedure
- 2.3.3 Granulocyte Transfusion
- 2.3.4 Antibiotic Therapy
- 2.3.5 Colony-Stimulating Factor Therapy
- 2.3.6 Others
- 2.4 Chemotherapy-Induced Neutropenia Treatment by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Ambulatory Surgical Center
- 2.4.3 Hospitals
- 2.4.4 Diagnostic Centers
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Chemotherapy-Induced Neutropenia Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Chemotherapy-Induced Neutropenia Treatment Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Chemotherapy-Induced Neutropenia Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global Chemotherapy-Induced Neutropenia Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global Chemotherapy-Induced Neutropenia Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Chemotherapy-Induced Neutropenia Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Chemotherapy-Induced Neutropenia Treatment, Product Type & Application
- 3.8 Global Manufacturers of Chemotherapy-Induced Neutropenia Treatment, Established Date
- 3.9 Global Chemotherapy-Induced Neutropenia Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceuticals Industries
- 4.1.1 Teva Pharmaceuticals Industries Company Information
- 4.1.2 Teva Pharmaceuticals Industries Business Overview
- 4.1.3 Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia Treatment Product Portfolio
- 4.1.5 Teva Pharmaceuticals Industries Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Chemotherapy-Induced Neutropenia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Chemotherapy-Induced Neutropenia Treatment Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Novartis AG
- 4.3.1 Novartis AG Company Information
- 4.3.2 Novartis AG Business Overview
- 4.3.3 Novartis AG Chemotherapy-Induced Neutropenia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis AG Chemotherapy-Induced Neutropenia Treatment Product Portfolio
- 4.3.5 Novartis AG Recent Developments
- 4.4 Baxter International
- 4.4.1 Baxter International Company Information
- 4.4.2 Baxter International Business Overview
- 4.4.3 Baxter International Chemotherapy-Induced Neutropenia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Baxter International Chemotherapy-Induced Neutropenia Treatment Product Portfolio
- 4.4.5 Baxter International Recent Developments
- 4.5 Amgen
- 4.5.1 Amgen Company Information
- 4.5.2 Amgen Business Overview
- 4.5.3 Amgen Chemotherapy-Induced Neutropenia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Amgen Chemotherapy-Induced Neutropenia Treatment Product Portfolio
- 4.5.5 Amgen Recent Developments
- 4.6 Ligand Pharmaceuticals
- 4.6.1 Ligand Pharmaceuticals Company Information
- 4.6.2 Ligand Pharmaceuticals Business Overview
- 4.6.3 Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia Treatment Product Portfolio
- 4.6.5 Ligand Pharmaceuticals Recent Developments
- 4.7 Dr. Reddy’s Laboratory
- 4.7.1 Dr. Reddy’s Laboratory Company Information
- 4.7.2 Dr. Reddy’s Laboratory Business Overview
- 4.7.3 Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia Treatment Product Portfolio
- 4.7.5 Dr. Reddy’s Laboratory Recent Developments
- 4.8 Biogenomics Limited
- 4.8.1 Biogenomics Limited Company Information
- 4.8.2 Biogenomics Limited Business Overview
- 4.8.3 Biogenomics Limited Chemotherapy-Induced Neutropenia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Biogenomics Limited Chemotherapy-Induced Neutropenia Treatment Product Portfolio
- 4.8.5 Biogenomics Limited Recent Developments
- 4.9 Apotex
- 4.9.1 Apotex Company Information
- 4.9.2 Apotex Business Overview
- 4.9.3 Apotex Chemotherapy-Induced Neutropenia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Apotex Chemotherapy-Induced Neutropenia Treatment Product Portfolio
- 4.9.5 Apotex Recent Developments
5 Global Chemotherapy-Induced Neutropenia Treatment Market Scenario by Region
- 5.1 Global Chemotherapy-Induced Neutropenia Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Chemotherapy-Induced Neutropenia Treatment Sales by Region: 2021-2032
- 5.2.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Region: 2021-2026
- 5.2.2 Global Chemotherapy-Induced Neutropenia Treatment Sales by Region: 2027-2032
- 5.3 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Region: 2021-2032
- 5.3.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Region: 2021-2026
- 5.3.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Region: 2027-2032
- 5.4 North America Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Country
- 5.4.1 North America Chemotherapy-Induced Neutropenia Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2032)
- 5.4.3 North America Chemotherapy-Induced Neutropenia Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Country
- 5.5.1 Europe Chemotherapy-Induced Neutropenia Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2032)
- 5.5.3 Europe Chemotherapy-Induced Neutropenia Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Country
- 5.6.1 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Country
- 5.7.1 South America Chemotherapy-Induced Neutropenia Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2032)
- 5.7.3 South America Chemotherapy-Induced Neutropenia Treatment Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Type (2021-2032)
- 6.1.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type (2021-2032)
- 6.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Type (2021-2032)
- 6.2.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Type (2021-2032)
- 6.3 Global Chemotherapy-Induced Neutropenia Treatment Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Application (2021-2032)
- 7.1.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application (2021-2032)
- 7.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Application (2021-2032)
- 7.2.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Application (2021-2032)
- 7.3 Global Chemotherapy-Induced Neutropenia Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Chemotherapy-Induced Neutropenia Treatment Value Chain Analysis
- 8.1.1 Chemotherapy-Induced Neutropenia Treatment Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Chemotherapy-Induced Neutropenia Treatment Production Mode & Process
- 8.2 Chemotherapy-Induced Neutropenia Treatment Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Chemotherapy-Induced Neutropenia Treatment Distributors
- 8.2.3 Chemotherapy-Induced Neutropenia Treatment Customers
9 Global Chemotherapy-Induced Neutropenia Treatment Analyzing Market Dynamics
- 9.1 Chemotherapy-Induced Neutropenia Treatment Industry Trends
- 9.2 Chemotherapy-Induced Neutropenia Treatment Industry Drivers
- 9.3 Chemotherapy-Induced Neutropenia Treatment Industry Opportunities and Challenges
- 9.4 Chemotherapy-Induced Neutropenia Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst